nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.134	0.197	CbGbCtD
Methazolamide—CYP2C19—Progesterone—uterine cancer	0.107	0.157	CbGbCtD
Methazolamide—CYP2C9—Progesterone—uterine cancer	0.089	0.131	CbGbCtD
Methazolamide—CYP2D6—Progesterone—uterine cancer	0.0814	0.119	CbGbCtD
Methazolamide—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0782	0.115	CbGbCtD
Methazolamide—CYP2E1—Etoposide—uterine cancer	0.0765	0.112	CbGbCtD
Methazolamide—CYP3A4—Progesterone—uterine cancer	0.0518	0.0759	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—uterine cancer	0.0249	0.0364	CbGbCtD
Methazolamide—CYP3A4—Etoposide—uterine cancer	0.0232	0.034	CbGbCtD
Methazolamide—CYP3A4—Doxorubicin—uterine cancer	0.0158	0.0232	CbGbCtD
Methazolamide—CA6—exocrine gland—uterine cancer	0.0089	0.151	CbGeAlD
Methazolamide—Hepatic necrosis—Progesterone—uterine cancer	0.00788	0.0325	CcSEcCtD
Methazolamide—Digestion impaired—Progesterone—uterine cancer	0.00685	0.0283	CcSEcCtD
Methazolamide—Digestion impaired—Medroxyprogesterone Acetate—uterine cancer	0.00621	0.0256	CcSEcCtD
Methazolamide—Metabolic acidosis—Etoposide—uterine cancer	0.00593	0.0245	CcSEcCtD
Methazolamide—Nephrolithiasis—Medroxyprogesterone Acetate—uterine cancer	0.00517	0.0213	CcSEcCtD
Methazolamide—Glycosuria—Medroxyprogesterone Acetate—uterine cancer	0.00513	0.0211	CcSEcCtD
Methazolamide—Blood disorder—Medroxyprogesterone Acetate—uterine cancer	0.00497	0.0205	CcSEcCtD
Methazolamide—CA5A—female reproductive system—uterine cancer	0.00446	0.0758	CbGeAlD
Methazolamide—CA7—renal system—uterine cancer	0.00371	0.063	CbGeAlD
Methazolamide—Hepatic failure—Progesterone—uterine cancer	0.0037	0.0153	CcSEcCtD
Methazolamide—Hepatic failure—Medroxyprogesterone Acetate—uterine cancer	0.00335	0.0138	CcSEcCtD
Methazolamide—Haemolytic anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00334	0.0138	CcSEcCtD
Methazolamide—CA2—exocrine gland—uterine cancer	0.00307	0.0521	CbGeAlD
Methazolamide—Aplastic anaemia—Dactinomycin—uterine cancer	0.00304	0.0125	CcSEcCtD
Methazolamide—Tingling sensation—Etoposide—uterine cancer	0.00292	0.012	CcSEcCtD
Methazolamide—Hepatic failure—Dactinomycin—uterine cancer	0.00262	0.0108	CcSEcCtD
Methazolamide—CA9—female reproductive system—uterine cancer	0.00261	0.0443	CbGeAlD
Methazolamide—Drowsiness—Progesterone—uterine cancer	0.00256	0.0106	CcSEcCtD
Methazolamide—Body temperature increased—Carboplatin—uterine cancer	0.00246	0.0101	CcSEcCtD
Methazolamide—CA12—renal system—uterine cancer	0.00241	0.0409	CbGeAlD
Methazolamide—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.00232	0.00958	CcSEcCtD
Methazolamide—Erythema multiforme—Progesterone—uterine cancer	0.00218	0.00897	CcSEcCtD
Methazolamide—Tinnitus—Progesterone—uterine cancer	0.00215	0.00885	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.00212	0.00873	CcSEcCtD
Methazolamide—CA5B—mammalian vulva—uterine cancer	0.00202	0.0343	CbGeAlD
Methazolamide—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00197	0.00813	CcSEcCtD
Methazolamide—Bone marrow depression—Epirubicin—uterine cancer	0.00195	0.00803	CcSEcCtD
Methazolamide—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00194	0.00802	CcSEcCtD
Methazolamide—Pancytopenia—Dactinomycin—uterine cancer	0.00193	0.00796	CcSEcCtD
Methazolamide—CA12—female reproductive system—uterine cancer	0.00193	0.0328	CbGeAlD
Methazolamide—CA1—renal system—uterine cancer	0.00191	0.0324	CbGeAlD
Methazolamide—Ill-defined disorder—Progesterone—uterine cancer	0.00186	0.00767	CcSEcCtD
Methazolamide—Malaise—Progesterone—uterine cancer	0.00181	0.00745	CcSEcCtD
Methazolamide—Bone marrow depression—Doxorubicin—uterine cancer	0.0018	0.00743	CcSEcCtD
Methazolamide—Vertigo—Progesterone—uterine cancer	0.0018	0.00742	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.0018	0.00741	CcSEcCtD
Methazolamide—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00178	0.00733	CcSEcCtD
Methazolamide—Convulsion—Progesterone—uterine cancer	0.00174	0.00716	CcSEcCtD
Methazolamide—CA5B—female reproductive system—uterine cancer	0.00173	0.0294	CbGeAlD
Methazolamide—Agranulocytosis—Dactinomycin—uterine cancer	0.00169	0.00697	CcSEcCtD
Methazolamide—Discomfort—Progesterone—uterine cancer	0.00168	0.00695	CcSEcCtD
Methazolamide—Ill-defined disorder—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.00695	CcSEcCtD
Methazolamide—Confusional state—Progesterone—uterine cancer	0.00165	0.0068	CcSEcCtD
Methazolamide—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00675	CcSEcCtD
Methazolamide—Anaphylactic shock—Progesterone—uterine cancer	0.00163	0.00674	CcSEcCtD
Methazolamide—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00673	CcSEcCtD
Methazolamide—Glycosuria—Epirubicin—uterine cancer	0.00162	0.00669	CcSEcCtD
Methazolamide—Blood disorder—Epirubicin—uterine cancer	0.00157	0.00649	CcSEcCtD
Methazolamide—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.00649	CcSEcCtD
Methazolamide—CA5B—vagina—uterine cancer	0.00157	0.0266	CbGeAlD
Methazolamide—Anorexia—Progesterone—uterine cancer	0.00156	0.00643	CcSEcCtD
Methazolamide—Erythema multiforme—Dactinomycin—uterine cancer	0.00154	0.00634	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.00153	0.00632	CcSEcCtD
Methazolamide—CA1—female reproductive system—uterine cancer	0.00153	0.026	CbGeAlD
Methazolamide—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.0063	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—uterine cancer	0.0015	0.00619	CcSEcCtD
Methazolamide—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.00616	CcSEcCtD
Methazolamide—CA4—renal system—uterine cancer	0.00149	0.0253	CbGeAlD
Methazolamide—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00148	0.00611	CcSEcCtD
Methazolamide—Paraesthesia—Progesterone—uterine cancer	0.00147	0.00605	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—uterine cancer	0.00146	0.006	CcSEcCtD
Methazolamide—Somnolence—Progesterone—uterine cancer	0.00145	0.00599	CcSEcCtD
Methazolamide—Dyspepsia—Progesterone—uterine cancer	0.00144	0.00594	CcSEcCtD
Methazolamide—Decreased appetite—Progesterone—uterine cancer	0.00142	0.00586	CcSEcCtD
Methazolamide—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.00582	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Progesterone—uterine cancer	0.00141	0.00582	CcSEcCtD
Methazolamide—Fatigue—Progesterone—uterine cancer	0.00141	0.00581	CcSEcCtD
Methazolamide—Pancytopenia—Etoposide—uterine cancer	0.0014	0.00576	CcSEcCtD
Methazolamide—Feeling abnormal—Progesterone—uterine cancer	0.00135	0.00556	CcSEcCtD
Methazolamide—CA2—epithelium—uterine cancer	0.00133	0.0226	CbGeAlD
Methazolamide—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.00549	CcSEcCtD
Methazolamide—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00543	CcSEcCtD
Methazolamide—Ill-defined disorder—Dactinomycin—uterine cancer	0.00131	0.00542	CcSEcCtD
Methazolamide—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00538	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.0013	0.00536	CcSEcCtD
Methazolamide—Urticaria—Progesterone—uterine cancer	0.0013	0.00536	CcSEcCtD
Methazolamide—Body temperature increased—Progesterone—uterine cancer	0.00129	0.00533	CcSEcCtD
Methazolamide—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00531	CcSEcCtD
Methazolamide—CA2—smooth muscle tissue—uterine cancer	0.00128	0.0218	CbGeAlD
Methazolamide—Melaena—Epirubicin—uterine cancer	0.00128	0.00529	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00128	0.00527	CcSEcCtD
Methazolamide—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00128	0.00527	CcSEcCtD
Methazolamide—Malaise—Dactinomycin—uterine cancer	0.00128	0.00527	CcSEcCtD
Methazolamide—Leukopenia—Dactinomycin—uterine cancer	0.00127	0.00523	CcSEcCtD
Methazolamide—CA2—decidua—uterine cancer	0.00126	0.0214	CbGeAlD
Methazolamide—CA2—renal system—uterine cancer	0.00124	0.021	CbGeAlD
Methazolamide—Aplastic anaemia—Epirubicin—uterine cancer	0.00123	0.00509	CcSEcCtD
Methazolamide—Agranulocytosis—Etoposide—uterine cancer	0.00122	0.00505	CcSEcCtD
Methazolamide—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.00503	CcSEcCtD
Methazolamide—CA4—female reproductive system—uterine cancer	0.00119	0.0203	CbGeAlD
Methazolamide—Discomfort—Dactinomycin—uterine cancer	0.00119	0.00491	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—uterine cancer	0.00119	0.0049	CcSEcCtD
Methazolamide—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00485	CcSEcCtD
Methazolamide—Asthenia—Progesterone—uterine cancer	0.00117	0.00484	CcSEcCtD
Methazolamide—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00483	CcSEcCtD
Methazolamide—CA2—mammalian vulva—uterine cancer	0.00116	0.0196	CbGeAlD
Methazolamide—Aplastic anaemia—Doxorubicin—uterine cancer	0.00114	0.00471	CcSEcCtD
Methazolamide—Diarrhoea—Progesterone—uterine cancer	0.00112	0.00461	CcSEcCtD
Methazolamide—Erythema multiforme—Etoposide—uterine cancer	0.00111	0.00459	CcSEcCtD
Methazolamide—Anorexia—Dactinomycin—uterine cancer	0.0011	0.00454	CcSEcCtD
Methazolamide—CA4—female gonad—uterine cancer	0.00109	0.0185	CbGeAlD
Methazolamide—Photosensitivity—Epirubicin—uterine cancer	0.00109	0.00448	CcSEcCtD
Methazolamide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00438	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—uterine cancer	0.00106	0.00438	CcSEcCtD
Methazolamide—Vomiting—Progesterone—uterine cancer	0.00104	0.00429	CcSEcCtD
Methazolamide—Rash—Progesterone—uterine cancer	0.00103	0.00425	CcSEcCtD
Methazolamide—Dermatitis—Progesterone—uterine cancer	0.00103	0.00425	CcSEcCtD
Methazolamide—Headache—Progesterone—uterine cancer	0.00102	0.00422	CcSEcCtD
Methazolamide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00418	CcSEcCtD
Methazolamide—CA5B—lymph node—uterine cancer	0.00101	0.0172	CbGeAlD
Methazolamide—Photosensitivity—Doxorubicin—uterine cancer	0.00101	0.00415	CcSEcCtD
Methazolamide—Decreased appetite—Dactinomycin—uterine cancer	0.001	0.00414	CcSEcCtD
Methazolamide—Dysgeusia—Etoposide—uterine cancer	0.001	0.00414	CcSEcCtD
Methazolamide—Fatigue—Dactinomycin—uterine cancer	0.000996	0.00411	CcSEcCtD
Methazolamide—CYP2E1—renal system—uterine cancer	0.000992	0.0168	CbGeAlD
Methazolamide—CA2—female reproductive system—uterine cancer	0.000991	0.0168	CbGeAlD
Methazolamide—Hepatic failure—Doxorubicin—uterine cancer	0.000982	0.00405	CcSEcCtD
Methazolamide—CYP2C19—vagina—uterine cancer	0.000978	0.0166	CbGeAlD
Methazolamide—Nausea—Progesterone—uterine cancer	0.000971	0.004	CcSEcCtD
Methazolamide—Feeling abnormal—Dactinomycin—uterine cancer	0.000952	0.00393	CcSEcCtD
Methazolamide—Ill-defined disorder—Etoposide—uterine cancer	0.000951	0.00392	CcSEcCtD
Methazolamide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000942	0.00388	CcSEcCtD
Methazolamide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000934	0.00385	CcSEcCtD
Methazolamide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000933	0.00385	CcSEcCtD
Methazolamide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000928	0.00383	CcSEcCtD
Methazolamide—Malaise—Etoposide—uterine cancer	0.000924	0.00381	CcSEcCtD
Methazolamide—Vertigo—Etoposide—uterine cancer	0.000921	0.0038	CcSEcCtD
Methazolamide—Leukopenia—Etoposide—uterine cancer	0.000917	0.00378	CcSEcCtD
Methazolamide—Body temperature increased—Dactinomycin—uterine cancer	0.000913	0.00377	CcSEcCtD
Methazolamide—CA2—female gonad—uterine cancer	0.000901	0.0153	CbGeAlD
Methazolamide—CA2—vagina—uterine cancer	0.000896	0.0152	CbGeAlD
Methazolamide—CA1—lymph node—uterine cancer	0.000894	0.0152	CbGeAlD
Methazolamide—Convulsion—Etoposide—uterine cancer	0.000888	0.00366	CcSEcCtD
Methazolamide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00088	0.00363	CcSEcCtD
Methazolamide—Discomfort—Etoposide—uterine cancer	0.000862	0.00355	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000859	0.00354	CcSEcCtD
Methazolamide—Confusional state—Etoposide—uterine cancer	0.000843	0.00348	CcSEcCtD
Methazolamide—CYP2C9—female reproductive system—uterine cancer	0.000838	0.0142	CbGeAlD
Methazolamide—Anaphylactic shock—Etoposide—uterine cancer	0.000836	0.00345	CcSEcCtD
Methazolamide—Asthenia—Dactinomycin—uterine cancer	0.000829	0.00342	CcSEcCtD
Methazolamide—CYP3A4—renal system—uterine cancer	0.000798	0.0136	CbGeAlD
Methazolamide—Anorexia—Etoposide—uterine cancer	0.000797	0.00329	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000795	0.00328	CcSEcCtD
Methazolamide—CYP2E1—female reproductive system—uterine cancer	0.000794	0.0135	CbGeAlD
Methazolamide—Diarrhoea—Dactinomycin—uterine cancer	0.000791	0.00326	CcSEcCtD
Methazolamide—CYP2D6—renal system—uterine cancer	0.000785	0.0133	CbGeAlD
Methazolamide—Pancytopenia—Epirubicin—uterine cancer	0.000783	0.00323	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—uterine cancer	0.000752	0.0031	CcSEcCtD
Methazolamide—Paraesthesia—Etoposide—uterine cancer	0.000751	0.0031	CcSEcCtD
Methazolamide—Somnolence—Etoposide—uterine cancer	0.000743	0.00307	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—uterine cancer	0.000735	0.00303	CcSEcCtD
Methazolamide—Vomiting—Dactinomycin—uterine cancer	0.000735	0.00303	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000729	0.00301	CcSEcCtD
Methazolamide—Rash—Dactinomycin—uterine cancer	0.000729	0.003	CcSEcCtD
Methazolamide—Decreased appetite—Etoposide—uterine cancer	0.000727	0.003	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—uterine cancer	0.000724	0.00299	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000722	0.00298	CcSEcCtD
Methazolamide—Fatigue—Etoposide—uterine cancer	0.000721	0.00297	CcSEcCtD
Methazolamide—Haematuria—Epirubicin—uterine cancer	0.000701	0.00289	CcSEcCtD
Methazolamide—CA4—lymph node—uterine cancer	0.000699	0.0119	CbGeAlD
Methazolamide—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000696	0.00287	CcSEcCtD
Methazolamide—Feeling abnormal—Etoposide—uterine cancer	0.000689	0.00284	CcSEcCtD
Methazolamide—Nausea—Dactinomycin—uterine cancer	0.000686	0.00283	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—uterine cancer	0.000686	0.00283	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—uterine cancer	0.00068	0.0028	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000674	0.00278	CcSEcCtD
Methazolamide—Urticaria—Etoposide—uterine cancer	0.000664	0.00274	CcSEcCtD
Methazolamide—Body temperature increased—Etoposide—uterine cancer	0.000661	0.00273	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—uterine cancer	0.000648	0.00267	CcSEcCtD
Methazolamide—CYP3A4—female reproductive system—uterine cancer	0.000639	0.0109	CbGeAlD
Methazolamide—Agranulocytosis—Doxorubicin—uterine cancer	0.000635	0.00262	CcSEcCtD
Methazolamide—CYP2D6—female reproductive system—uterine cancer	0.000629	0.0107	CbGeAlD
Methazolamide—Erythema multiforme—Epirubicin—uterine cancer	0.000624	0.00257	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—uterine cancer	0.000615	0.00254	CcSEcCtD
Methazolamide—Asthenia—Etoposide—uterine cancer	0.0006	0.00247	CcSEcCtD
Methazolamide—CA2—lymph node—uterine cancer	0.000579	0.00984	CbGeAlD
Methazolamide—Erythema multiforme—Doxorubicin—uterine cancer	0.000577	0.00238	CcSEcCtD
Methazolamide—CYP2D6—female gonad—uterine cancer	0.000572	0.00972	CbGeAlD
Methazolamide—Diarrhoea—Etoposide—uterine cancer	0.000572	0.00236	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—uterine cancer	0.000569	0.00235	CcSEcCtD
Methazolamide—Dysgeusia—Epirubicin—uterine cancer	0.000562	0.00232	CcSEcCtD
Methazolamide—Ill-defined disorder—Epirubicin—uterine cancer	0.000533	0.0022	CcSEcCtD
Methazolamide—Vomiting—Etoposide—uterine cancer	0.000532	0.00219	CcSEcCtD
Methazolamide—Rash—Etoposide—uterine cancer	0.000527	0.00217	CcSEcCtD
Methazolamide—Dermatitis—Etoposide—uterine cancer	0.000527	0.00217	CcSEcCtD
Methazolamide—Headache—Etoposide—uterine cancer	0.000524	0.00216	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—uterine cancer	0.00052	0.00215	CcSEcCtD
Methazolamide—Malaise—Epirubicin—uterine cancer	0.000518	0.00214	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—uterine cancer	0.000516	0.00213	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—uterine cancer	0.000514	0.00212	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—uterine cancer	0.000498	0.00205	CcSEcCtD
Methazolamide—Nausea—Etoposide—uterine cancer	0.000497	0.00205	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—uterine cancer	0.000493	0.00203	CcSEcCtD
Methazolamide—Discomfort—Epirubicin—uterine cancer	0.000483	0.00199	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—uterine cancer	0.000479	0.00198	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—uterine cancer	0.000477	0.00197	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—uterine cancer	0.000476	0.00196	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—uterine cancer	0.000473	0.00195	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—uterine cancer	0.000469	0.00193	CcSEcCtD
Methazolamide—Convulsion—Doxorubicin—uterine cancer	0.00046	0.0019	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—uterine cancer	0.000447	0.00184	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—uterine cancer	0.000447	0.00184	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—uterine cancer	0.000437	0.0018	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—uterine cancer	0.000434	0.00179	CcSEcCtD
Methazolamide—Paraesthesia—Epirubicin—uterine cancer	0.000421	0.00174	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—uterine cancer	0.000417	0.00172	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—uterine cancer	0.000413	0.00171	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—uterine cancer	0.000413	0.0017	CcSEcCtD
Methazolamide—Decreased appetite—Epirubicin—uterine cancer	0.000408	0.00168	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000405	0.00167	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—uterine cancer	0.000404	0.00167	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—uterine cancer	0.000389	0.00161	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—uterine cancer	0.000386	0.00159	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—uterine cancer	0.000386	0.00159	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—uterine cancer	0.000382	0.00157	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—uterine cancer	0.000377	0.00156	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000374	0.00154	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—uterine cancer	0.000374	0.00154	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—uterine cancer	0.000372	0.00154	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—uterine cancer	0.000371	0.00153	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—uterine cancer	0.000357	0.00147	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—uterine cancer	0.000345	0.00142	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—uterine cancer	0.000343	0.00141	CcSEcCtD
Methazolamide—Asthenia—Epirubicin—uterine cancer	0.000336	0.00139	CcSEcCtD
Methazolamide—Diarrhoea—Epirubicin—uterine cancer	0.000321	0.00132	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—uterine cancer	0.000311	0.00128	CcSEcCtD
Methazolamide—Vomiting—Epirubicin—uterine cancer	0.000298	0.00123	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—uterine cancer	0.000297	0.00122	CcSEcCtD
Methazolamide—Rash—Epirubicin—uterine cancer	0.000296	0.00122	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—uterine cancer	0.000295	0.00122	CcSEcCtD
Methazolamide—Headache—Epirubicin—uterine cancer	0.000294	0.00121	CcSEcCtD
Methazolamide—Nausea—Epirubicin—uterine cancer	0.000278	0.00115	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—uterine cancer	0.000276	0.00114	CcSEcCtD
Methazolamide—Rash—Doxorubicin—uterine cancer	0.000273	0.00113	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—uterine cancer	0.000273	0.00113	CcSEcCtD
Methazolamide—Headache—Doxorubicin—uterine cancer	0.000272	0.00112	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—uterine cancer	0.000258	0.00106	CcSEcCtD
Methazolamide—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	4.53e-05	0.00274	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	4.51e-05	0.00273	CbGpPWpGaD
Methazolamide—CA14—Metabolism—AKR1C3—uterine cancer	4.51e-05	0.00273	CbGpPWpGaD
Methazolamide—CA12—Metabolism—RRM2—uterine cancer	4.4e-05	0.00266	CbGpPWpGaD
Methazolamide—CA6—Metabolism—AKR1C3—uterine cancer	4.39e-05	0.00266	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—AKR1C3—uterine cancer	4.39e-05	0.00266	CbGpPWpGaD
Methazolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.36e-05	0.00264	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CYP11A1—uterine cancer	4.34e-05	0.00263	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CYP11A1—uterine cancer	4.34e-05	0.00263	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKR1B1—uterine cancer	4.33e-05	0.00262	CbGpPWpGaD
Methazolamide—CA9—Metabolism—STAR—uterine cancer	4.33e-05	0.00262	CbGpPWpGaD
Methazolamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.3e-05	0.00261	CbGpPWpGaD
Methazolamide—CA12—Metabolism—DCN—uterine cancer	4.27e-05	0.00259	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	4.24e-05	0.00257	CbGpPWpGaD
Methazolamide—CA4—Metabolism—POLD1—uterine cancer	4.21e-05	0.00255	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	4.21e-05	0.00255	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	4.19e-05	0.00253	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	4.15e-05	0.00251	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	4.11e-05	0.00249	CbGpPWpGaD
Methazolamide—CA7—Metabolism—AKR1C3—uterine cancer	4.1e-05	0.00248	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—AKR1C3—uterine cancer	4.1e-05	0.00248	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CDKN2A—uterine cancer	4.06e-05	0.00246	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—CYP19A1—uterine cancer	4.05e-05	0.00245	CbGpPWpGaD
Methazolamide—CA2—Metabolism—POLD1—uterine cancer	4.03e-05	0.00244	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CYP11A1—uterine cancer	4.02e-05	0.00244	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—CYP19A1—uterine cancer	3.99e-05	0.00242	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	3.95e-05	0.00239	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKR1C1—uterine cancer	3.94e-05	0.00238	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	3.9e-05	0.00236	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	3.87e-05	0.00234	CbGpPWpGaD
Methazolamide—CA1—Metabolism—POLD1—uterine cancer	3.87e-05	0.00234	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	3.85e-05	0.00233	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	3.82e-05	0.00231	CbGpPWpGaD
Methazolamide—CA12—Metabolism—AKR1C3—uterine cancer	3.8e-05	0.0023	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKR1C1—uterine cancer	3.77e-05	0.00228	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.77e-05	0.00228	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CXCL8—uterine cancer	3.68e-05	0.00223	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	3.64e-05	0.0022	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKR1C1—uterine cancer	3.62e-05	0.00219	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	3.6e-05	0.00218	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CDKN1B—uterine cancer	3.59e-05	0.00218	CbGpPWpGaD
Methazolamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.54e-05	0.00214	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CYP19A1—uterine cancer	3.51e-05	0.00213	CbGpPWpGaD
Methazolamide—CA14—Metabolism—STK11—uterine cancer	3.51e-05	0.00213	CbGpPWpGaD
Methazolamide—CA4—Metabolism—RRM2—uterine cancer	3.51e-05	0.00212	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.44e-05	0.00208	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—STK11—uterine cancer	3.42e-05	0.00207	CbGpPWpGaD
Methazolamide—CA6—Metabolism—STK11—uterine cancer	3.42e-05	0.00207	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CYP19A1—uterine cancer	3.42e-05	0.00207	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CYP19A1—uterine cancer	3.42e-05	0.00207	CbGpPWpGaD
Methazolamide—CA4—Metabolism—DCN—uterine cancer	3.41e-05	0.00206	CbGpPWpGaD
Methazolamide—CA9—Metabolism—POLD1—uterine cancer	3.4e-05	0.00206	CbGpPWpGaD
Methazolamide—CA2—Metabolism—RRM2—uterine cancer	3.36e-05	0.00204	CbGpPWpGaD
Methazolamide—CA2—Metabolism—DCN—uterine cancer	3.27e-05	0.00198	CbGpPWpGaD
Methazolamide—CA1—Metabolism—RRM2—uterine cancer	3.22e-05	0.00195	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP11A1—uterine cancer	3.21e-05	0.00194	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CYP19A1—uterine cancer	3.2e-05	0.00193	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—STK11—uterine cancer	3.2e-05	0.00193	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CYP19A1—uterine cancer	3.2e-05	0.00193	CbGpPWpGaD
Methazolamide—CA7—Metabolism—STK11—uterine cancer	3.2e-05	0.00193	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKR1C1—uterine cancer	3.18e-05	0.00193	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—EP300—uterine cancer	3.16e-05	0.00191	CbGpPWpGaD
Methazolamide—CA1—Metabolism—DCN—uterine cancer	3.13e-05	0.0019	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	3.12e-05	0.00189	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.09e-05	0.00187	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	3.08e-05	0.00186	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP11A1—uterine cancer	3.08e-05	0.00186	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKR1C3—uterine cancer	3.03e-05	0.00183	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—VEGFA—uterine cancer	2.99e-05	0.00181	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CYP19A1—uterine cancer	2.96e-05	0.00179	CbGpPWpGaD
Methazolamide—CA12—Metabolism—STK11—uterine cancer	2.96e-05	0.00179	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP11A1—uterine cancer	2.95e-05	0.00179	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKR1C3—uterine cancer	2.91e-05	0.00176	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.87e-05	0.00174	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	2.85e-05	0.00172	CbGpPWpGaD
Methazolamide—CA9—Metabolism—RRM2—uterine cancer	2.84e-05	0.00172	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.83e-05	0.00172	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	2.81e-05	0.0017	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKR1C3—uterine cancer	2.79e-05	0.00169	CbGpPWpGaD
Methazolamide—CA9—Metabolism—DCN—uterine cancer	2.75e-05	0.00167	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.72e-05	0.00165	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.72e-05	0.00165	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.71e-05	0.00164	CbGpPWpGaD
Methazolamide—CA14—Metabolism—MTHFR—uterine cancer	2.64e-05	0.0016	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP11A1—uterine cancer	2.59e-05	0.00157	CbGpPWpGaD
Methazolamide—CA6—Metabolism—MTHFR—uterine cancer	2.57e-05	0.00156	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—MTHFR—uterine cancer	2.57e-05	0.00156	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.55e-05	0.00155	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.52e-05	0.00152	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.48e-05	0.0015	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.48e-05	0.0015	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKR1C3—uterine cancer	2.45e-05	0.00148	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—MTHFR—uterine cancer	2.4e-05	0.00145	CbGpPWpGaD
Methazolamide—CA7—Metabolism—MTHFR—uterine cancer	2.4e-05	0.00145	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.38e-05	0.00144	CbGpPWpGaD
Methazolamide—CA4—Metabolism—STK11—uterine cancer	2.36e-05	0.00143	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP19A1—uterine cancer	2.36e-05	0.00143	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP19A1—uterine cancer	2.26e-05	0.00137	CbGpPWpGaD
Methazolamide—CA2—Metabolism—STK11—uterine cancer	2.26e-05	0.00137	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—uterine cancer	2.26e-05	0.00137	CbGpPWpGaD
Methazolamide—CA12—Metabolism—MTHFR—uterine cancer	2.22e-05	0.00135	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SRD5A2—uterine cancer	2.18e-05	0.00132	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NDUFB11—uterine cancer	2.18e-05	0.00132	CbGpPWpGaD
Methazolamide—CA1—Metabolism—STK11—uterine cancer	2.17e-05	0.00131	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP19A1—uterine cancer	2.17e-05	0.00131	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2e-05	0.00121	CbGpPWpGaD
Methazolamide—CA9—Metabolism—STK11—uterine cancer	1.91e-05	0.00116	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP19A1—uterine cancer	1.91e-05	0.00116	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.88e-05	0.00114	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.85e-05	0.00112	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.82e-05	0.0011	CbGpPWpGaD
Methazolamide—CA4—Metabolism—MTHFR—uterine cancer	1.77e-05	0.00107	CbGpPWpGaD
Methazolamide—CA2—Metabolism—MTHFR—uterine cancer	1.7e-05	0.00103	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.68e-05	0.00102	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.68e-05	0.00102	CbGpPWpGaD
Methazolamide—CA1—Metabolism—MTHFR—uterine cancer	1.63e-05	0.000987	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.63e-05	0.000987	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—STAR—uterine cancer	1.57e-05	0.000952	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKR1B1—uterine cancer	1.57e-05	0.000952	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.54e-05	0.000934	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.54e-05	0.000934	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.54e-05	0.000932	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.53e-05	0.000926	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.53e-05	0.000926	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.49e-05	0.0009	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTEN—uterine cancer	1.47e-05	0.000889	CbGpPWpGaD
Methazolamide—CA9—Metabolism—MTHFR—uterine cancer	1.43e-05	0.000868	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTEN—uterine cancer	1.43e-05	0.000866	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTEN—uterine cancer	1.43e-05	0.000866	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.4e-05	0.00085	CbGpPWpGaD
Methazolamide—CA14—Metabolism—EP300—uterine cancer	1.4e-05	0.000848	CbGpPWpGaD
Methazolamide—CA6—Metabolism—EP300—uterine cancer	1.36e-05	0.000826	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—EP300—uterine cancer	1.36e-05	0.000826	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTEN—uterine cancer	1.34e-05	0.000809	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTEN—uterine cancer	1.34e-05	0.000809	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—EP300—uterine cancer	1.27e-05	0.000771	CbGpPWpGaD
Methazolamide—CA7—Metabolism—EP300—uterine cancer	1.27e-05	0.000771	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTEN—uterine cancer	1.24e-05	0.000749	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—POLD1—uterine cancer	1.23e-05	0.000747	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.21e-05	0.000735	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—STAR—uterine cancer	1.21e-05	0.000735	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.2e-05	0.000726	CbGpPWpGaD
Methazolamide—CA12—Metabolism—EP300—uterine cancer	1.18e-05	0.000715	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKR1C1—uterine cancer	1.15e-05	0.000699	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.12e-05	0.000676	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—STAR—uterine cancer	1.12e-05	0.000676	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—STAR—uterine cancer	1.11e-05	0.00067	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.11e-05	0.00067	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.09e-05	0.000662	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PIK3CA—uterine cancer	1.04e-05	0.000627	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—RRM2—uterine cancer	1.03e-05	0.000623	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PIK3CA—uterine cancer	1.01e-05	0.000611	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PIK3CA—uterine cancer	1.01e-05	0.000611	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.01e-05	0.000611	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.01e-05	0.000611	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—DCN—uterine cancer	9.99e-06	0.000605	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTEN—uterine cancer	9.87e-06	0.000598	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—POLD1—uterine cancer	9.52e-06	0.000576	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTEN—uterine cancer	9.46e-06	0.000573	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PIK3CA—uterine cancer	9.42e-06	0.000571	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PIK3CA—uterine cancer	9.42e-06	0.000571	CbGpPWpGaD
Methazolamide—CA4—Metabolism—EP300—uterine cancer	9.41e-06	0.00057	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP11A1—uterine cancer	9.41e-06	0.00057	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTEN—uterine cancer	9.07e-06	0.000549	CbGpPWpGaD
Methazolamide—CA2—Metabolism—EP300—uterine cancer	9.02e-06	0.000546	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKR1C1—uterine cancer	8.9e-06	0.000539	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKR1C3—uterine cancer	8.89e-06	0.000538	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—POLD1—uterine cancer	8.76e-06	0.00053	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PIK3CA—uterine cancer	8.73e-06	0.000529	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—POLD1—uterine cancer	8.68e-06	0.000526	CbGpPWpGaD
Methazolamide—CA1—Metabolism—EP300—uterine cancer	8.65e-06	0.000524	CbGpPWpGaD
Methazolamide—CA14—Metabolism—AKT1—uterine cancer	8.46e-06	0.000512	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—AKT1—uterine cancer	8.25e-06	0.000499	CbGpPWpGaD
Methazolamide—CA6—Metabolism—AKT1—uterine cancer	8.25e-06	0.000499	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKR1C1—uterine cancer	8.19e-06	0.000496	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKR1C1—uterine cancer	8.12e-06	0.000492	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTEN—uterine cancer	7.98e-06	0.000483	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—RRM2—uterine cancer	7.94e-06	0.000481	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—DCN—uterine cancer	7.71e-06	0.000467	CbGpPWpGaD
Methazolamide—CA7—Metabolism—AKT1—uterine cancer	7.7e-06	0.000466	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—AKT1—uterine cancer	7.7e-06	0.000466	CbGpPWpGaD
Methazolamide—CA9—Metabolism—EP300—uterine cancer	7.61e-06	0.00046	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—RRM2—uterine cancer	7.3e-06	0.000442	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—STAR—uterine cancer	7.3e-06	0.000442	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKR1B1—uterine cancer	7.3e-06	0.000442	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP11A1—uterine cancer	7.26e-06	0.00044	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—RRM2—uterine cancer	7.24e-06	0.000438	CbGpPWpGaD
Methazolamide—CA12—Metabolism—AKT1—uterine cancer	7.13e-06	0.000432	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—DCN—uterine cancer	7.09e-06	0.000429	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—DCN—uterine cancer	7.03e-06	0.000425	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PIK3CA—uterine cancer	6.96e-06	0.000422	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—STK11—uterine cancer	6.92e-06	0.000419	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP19A1—uterine cancer	6.92e-06	0.000419	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKR1C3—uterine cancer	6.86e-06	0.000415	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.68e-06	0.000404	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PIK3CA—uterine cancer	6.68e-06	0.000404	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.62e-06	0.000401	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PIK3CA—uterine cancer	6.4e-06	0.000387	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKR1C3—uterine cancer	6.31e-06	0.000382	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKR1C3—uterine cancer	6.25e-06	0.000378	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—POLD1—uterine cancer	5.72e-06	0.000347	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKT1—uterine cancer	5.69e-06	0.000344	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PIK3CA—uterine cancer	5.63e-06	0.000341	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKT1—uterine cancer	5.45e-06	0.00033	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.35e-06	0.000324	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—STK11—uterine cancer	5.34e-06	0.000323	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP19A1—uterine cancer	5.34e-06	0.000323	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKT1—uterine cancer	5.23e-06	0.000317	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—MTHFR—uterine cancer	5.2e-06	0.000315	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.01e-06	0.000304	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—STK11—uterine cancer	4.91e-06	0.000297	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.91e-06	0.000297	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.87e-06	0.000295	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—STK11—uterine cancer	4.87e-06	0.000295	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.78e-06	0.000289	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—RRM2—uterine cancer	4.77e-06	0.000289	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—DCN—uterine cancer	4.63e-06	0.000281	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKT1—uterine cancer	4.6e-06	0.000278	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.57e-06	0.000277	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.37e-06	0.000264	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.36e-06	0.000264	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.12e-06	0.00025	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—MTHFR—uterine cancer	4.01e-06	0.000243	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—MTHFR—uterine cancer	3.69e-06	0.000223	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—MTHFR—uterine cancer	3.66e-06	0.000222	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.54e-06	0.000214	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.22e-06	0.000195	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—STK11—uterine cancer	3.21e-06	0.000194	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.21e-06	0.000194	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTEN—uterine cancer	2.89e-06	0.000175	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—EP300—uterine cancer	2.76e-06	0.000167	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—MTHFR—uterine cancer	2.41e-06	0.000146	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTEN—uterine cancer	2.23e-06	0.000135	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—EP300—uterine cancer	2.13e-06	0.000129	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTEN—uterine cancer	2.05e-06	0.000124	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PIK3CA—uterine cancer	2.04e-06	0.000124	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTEN—uterine cancer	2.04e-06	0.000123	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—EP300—uterine cancer	1.96e-06	0.000119	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—EP300—uterine cancer	1.94e-06	0.000118	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKT1—uterine cancer	1.67e-06	0.000101	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.58e-06	9.54e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.45e-06	8.77e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.44e-06	8.7e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTEN—uterine cancer	1.34e-06	8.13e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKT1—uterine cancer	1.29e-06	7.79e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—EP300—uterine cancer	1.28e-06	7.75e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKT1—uterine cancer	1.18e-06	7.17e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKT1—uterine cancer	1.17e-06	7.1e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PIK3CA—uterine cancer	9.47e-07	5.73e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKT1—uterine cancer	7.74e-07	4.68e-05	CbGpPWpGaD
